Novo Nordisk invests in amyloidosis pipeline
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
Sanofi invests heavily in multiple myeloma pipeline
Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
NFL Biosciences goes public, raises €5m
French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.
Promethera bags €20m for liver failure treatment
With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.
IMI ramps up COVID fund
The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.
Agriculture ministers commit to global trade rules
Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.
HepaRegeniX: €11m for liver disease treatment
HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.
Iberian biotech newcomer
The geographical proximity of Spain’s Northwestern region Galicia to Northern Portugal is a key factor for the birth of the new bioregion CT-Bio. This achievement looks forward to improving business competitiveness and the consolidation of the biotech and life sciences sector internationally.
Cellestia: €20m to get to Phase II
Basel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
€7.34m for cancer vaccine developer
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.